DMD and Duchenne muscular dystrophy: Eteplirsen (or Exondys 51, Sarepta Therapeutics) was the first drug that received accelerated approval for treating DMD patients with a confirmed mutation of the dystrophin gene amenable to exon 51 skipping (Table S2).